- RDM* biotech/pharma
- Founded in: 2003
- Staff: 61
- Indications: G00 - G99 I60 - I99 E00 - E90
- Topic: Human health
- Cluster Membership: LISAvienna
- Profile: AFFiRiS develops first-in-class specific active immunotherapies (SAIT) for the prevention and treatment of chronic illnesses. SAIT candidates are based on a flexible modular system consisting of peptides conjugated to carrier proteins and an adjuvant. Our proprietary AFFITOME®-Technology delivers peptides that are close variants of a target specific epitope and are optimized for immunogenicity, thereby inducing an antibody response that is cross-reactive to the original target.
- R&D: Our clinical stage projects focus on Atherosclerosis prevention targeting PCSK9 and Parkinson’s disease targeting α synuclein. Our pre-clinical projects focus on Huntington's targeting mutHTT and other undisclosed targets.